Columbus, OH, United States of America

Sandip Madhukar Vibhute

This inventor holds 3 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Hendrix College, The Ohio State University. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sandip Madhukar Vibhute. Retrieved from https://idiyas.com/inventor/sandip-madhukar-vibhute

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in DHODH Inhibition by Sandip Madhukar Vibhute

Introduction

Sandip Madhukar Vibhute, an accomplished inventor based in Columbus, OH, has made notable contributions to the field of pharmaceutical science. With two patents to his name, his innovations focus on innovative methods and compositions aimed at inhibiting dihydroorotate dehydrogenase (DHODH), an enzyme implicated in various diseases, including cancer.

Latest Patents

Vibhute's most recent patents encompass groundbreaking compounds identified as 3,4,6,8-substituted-2-([1,1'-biphenyl]-4-yl)quinoline analogs. These compounds serve as inhibitors of dihydroorotate dehydrogenase and demonstrate enhanced pharmacokinetic properties. Their clinical applications are diverse and significant, targeting a variety of disorders where DHODH inhibition can be therapeutically beneficial. This includes hematological cancers such as acute myeloid leukemia (AML), autoimmune disorders, graft-versus-host diseases, and conditions associated with T-cell proliferation. Notably, these compounds exhibit unique pharmacokinetics characterized by flip-flop kinetics when taken orally, indicating that absorption rate surpasses elimination rate, thus providing a sustained pharmacokinetic profile.

Career Highlights

Throughout his career, Sandip has contributed his expertise to organizations such as the Ohio State Innovation Foundation and Hendrix College. His innovative work in the pharmaceutical field continues to draw attention due to its implications for treatment strategies in cancer and autoimmune disorders.

Collaborations

Vibhute has had the opportunity to collaborate with esteemed professionals, including John C. Byrd and Thomas E. Goodwin. These collaborations have likely enhanced his research outcomes and expanded the impact of his inventions in the medical field.

Conclusion

Sandip Madhukar Vibhute exemplifies the spirit of innovation and dedication to improving therapeutic approaches through his pioneering work on DHODH inhibitors. His contributions not only represent significant advancements in pharmaceutical science but also offer promise for effective treatments for complex diseases. As research continues in this domain, the potential benefits of his inventions may lead to breakthroughs in patient care and treatment methodologies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…